In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel disease, joining a race to bring the first drug in the class to market.Sanofi has acquired rights to co-develop and co-market Teva’s TEV-48574, currently in […]